CanSino Biologics Inc.
CanSino Biologics Inc. Fundamental Analysis
CanSino Biologics Inc. (6185.HK) shows weak financial fundamentals with a PE ratio of 262.90, profit margin of 2.60%, and ROE of 0.56%. The company generates $1.4B in annual revenue with strong year-over-year growth of 26.18%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 49.2/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 6185.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak6185.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate6185.HK shows balanced valuation metrics.
Growth Score
Moderate6185.HK shows steady but slowing expansion.
Financial Health Score
Excellent6185.HK maintains a strong and stable balance sheet.
Profitability Score
Weak6185.HK struggles to sustain strong margins.
Key Financial Metrics
Is 6185.HK Expensive or Cheap?
P/E Ratio
6185.HK trades at 262.90 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 6185.HK's PEG of 0.90 indicates potential undervaluation.
Price to Book
The market values CanSino Biologics Inc. at 1.47 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 161.39 times EBITDA. This signals the market has high growth expectations.
How Well Does 6185.HK Make Money?
Net Profit Margin
For every $100 in sales, CanSino Biologics Inc. keeps $2.60 as profit after all expenses.
Operating Margin
Core operations generate -4.31 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.56 in profit for every $100 of shareholder equity.
ROA
CanSino Biologics Inc. generates $0.39 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
CanSino Biologics Inc. produces operating cash flow of $154.98M, showing steady but balanced cash generation.
Free Cash Flow
CanSino Biologics Inc. generates weak or negative free cash flow of $-174.90M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.50 in free cash annually.
FCF Yield
6185.HK converts -1.33% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
262.90
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.90
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.47
vs 25 benchmark
P/S Ratio
Price to sales ratio
9.21
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.26
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.67
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.006
vs 25 benchmark
ROA
Return on assets percentage
0.004
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How 6185.HK Stacks Against Its Sector Peers
| Metric | 6185.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 262.90 | 28.66 | Worse (Expensive) |
| ROE | 0.56% | 671.00% | Weak |
| Net Margin | 2.60% | -44168.00% (disorted) | Weak |
| Debt/Equity | 0.26 | 0.33 | Strong (Low Leverage) |
| Current Ratio | 3.67 | 4.49 | Strong Liquidity |
| ROA | 0.39% | -17052.00% (disorted) | Weak |
6185.HK outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews CanSino Biologics Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
3804.70%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
106.40%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
126.36%
Industry Style: Defensive, Growth, Innovation
High Growth